[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594634":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":35,"locations":45,"responsibleParty":64,"collaborators":26,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":26,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Shenyang Sunshine Pharmaceutical Co., LTD.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1","EXPERIMENTAL","advanced gastric cancer and breast cancer that have failed standard treatment",[13],"Drug: SSGJ-705",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2","previously untreated advanced gastric cancer and lung cancer",[18,19],"Drug: PD-1\u002FL1 inhibitor combined with chemotherapy","Drug: SSGJ-705 combined with chemotherapy",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","SSGJ-705","anti-PD-1 (programmed cell death protein 1) and anti-HER2 (Human Epidermal GrowthFactor Receptor 2)bispecifc antibody",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"PD-1\u002FL1 inhibitor combined with chemotherapy","Immune checkpoint inhibitors",[15],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"SSGJ-705 combined with chemotherapy","anti-PD-1 and anti-HER2 bispecifc antibody",[15],[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Jieer Ying, M.D","CONTACT","86-13858195803","hzyingjieer@163.com",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Meifang Zheng, M.D.","86-15258894828","794998553@qq.com",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":26,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Zhejiang Cancer Hospital","RECRUITING","Hangzhou","Zhejiang","China","CN",{"type":54,"coordinates":55},"Point",[56,57],120.16142,30.29365,{"lat":57,"lon":56},[60],{"name":61,"role":38,"phone":62,"phoneExt":26,"email":63},"Feiyan Li","0571-88122482","lify1697@zjcc.org.cn",{"type":65,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100594634","phase-2-ssgj-705-monotherapy-and-combination-therapy-in-advanced-her2-expressing-solid-tumors-100594634",false,"NCT07022002","SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","A Phase II Study to Evaluate the Safety and Efficacy of SSGJ-705 Monotherapy and Combination Therapy in Patients With Advanced HER2-Expressing Solid Tumors","Inclusion Criteria:\n\n* Males and\u002For females over age 18.\n* Histologically and\u002For cytologically documented local advanced or metastatic non-Small Cell Lung Cancer（NSCLC），Breast Cancer（BC）or Gastric\u002FGastroesophageal Junction Cancer （G\u002FGEJC).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Expected survival \\>3 months.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Any remaining adverse events (AEs) \\> grade 1 from prior anti-tumor treatment as per Common Terminology Criteria for Adverse Events（CTCAE） v5. 0, with exception of hair loss, fatigue, and grade 2 peripheral neurotoxicity.\n* Pregnant or nursing women or women\u002Fmen who are ready to give birth.\n* symptomatic central nervous system metastasis.\n* Allergy to other antibody drugs or any excipients in the study drugs.\n* Inadequate organ or bone marrow function.","ALL","18 Years","75 Years",{"count":77,"type":78},340,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.",[84],"Locally Advanced, Recurrent or Metastatic Malignancies",[86],"advanced malignancies","2025-08-01",{"date":89,"type":90},"2025-08-03","ACTUAL",{"date":92,"type":90},"2025-07-30",{"date":94,"type":78},"2027-12-12",{"name":5,"class":6},1]